Potential Adverse Effects of Novel Drug Therapies in Multiple Myeloma Treatment by Cluster, Anndria
DePaul University 
Via Sapientiae 
Grace Peterson Nursing Research Colloquium 2017 
Aug 18th, 10:00 AM - 11:30 AM 
Potential Adverse Effects of Novel Drug Therapies in Multiple 
Myeloma Treatment 
Anndria Cluster 
andicluster@gmail.com 
Follow this and additional works at: https://via.library.depaul.edu/nursing-colloquium 
 Part of the Nursing Commons 
Cluster, Anndria, "Potential Adverse Effects of Novel Drug Therapies in Multiple Myeloma Treatment" 
(2017). Grace Peterson Nursing Research Colloquium. 48. 
https://via.library.depaul.edu/nursing-colloquium/2017/Summer_2017/48 
This Event is brought to you for free and open access by the School of Nursing at Via Sapientiae. It has been 
accepted for inclusion in Grace Peterson Nursing Research Colloquium by an authorized administrator of Via 
Sapientiae. For more information, please contact digitalservices@depaul.edu. 
Anndria	Cluster,	BS,	Joseph	D.	Tariman,	PhD,	RN,	ANP-BC,	FAAN	
Purpose 
Background 
Conclusion Learning Objectives 
Article Selection 
•  Articles were located utilizing combinations of the following 
Medical Subject Heading (MeSH) terms: multiple myeloma, 
novel therapy, adverse effects, and management 
•  Searches were conducted utilizing CIHNAL and PubMed, 
between 2003 and 2016, yielding 66 articles 
•  36 articles were utilized, and papers that only focused on 
adverse effects of bisphosphonates and growth factors  
Results 
The final 36 articles used were categorized by level of evidence 
according to Melnyk and Fineout-Overholt’s hierarchy of evidence 
(2011) to appraise the strength of evidence for reported self-
management strategies.  
 
1.  The most common adverse effects are outlined in Table 1, 
organized by the drug studied in the articles.  
2.  Majority (N=32 out of 36) of self-management techniques came 
from articles that were categorized as single descriptive studies, 
review papers, or expert opinions, all of which are Level 6 and 7 
in the hierarchy of evidence 
3.  These techniques include methods such as the use of 
antiemetic drugs, anti-diarrheal, laxative, blood transfusions, 
Erythrocyte Stimulating Agents, antibiotics, anti-virals, treatment 
dose adjustments and dose delays, and monitoring and 
immediate reporting of adverse events such as peripheral 
neuropathy to health care team 
4.  The only self- management techniques supported by level 2 
evidence are the use of aspirin, warfarin, and enoxaparin as 
VTE prophylaxis, indicating that randomized controlled trials had 
been performed  
These findings underscore the need for randomized controlled trials 
to be conducted to assess the effectiveness of the self-
management techniques to ameliorate adverse effects 
There is a need for individualized, evidence-based education that 
can be given to patients to promote management of these effects 
Treating MM has evolved greatly in the recent years, and 
management of adverse effects needs to catch up to promote 
patient well-being and quality of life 
MM has undergone a surge in novel therapies to 
treat the disease over the past decade. It is vital to 
educate patients on the common adverse effects of 
these new treatments, as well as the self-
management strategies that can be implemented to 
maintain and promote their quality of life.  
The purpose of this integrative literature review is to 
synthesize the potential side effects of the novel drug 
therapies to treat multiple myeloma and to develop 
evidence- based self-management techniques of the 
potential side effects to increase quality of life in the 
patient. 
1.  Identify the most common adverse effects 
associated with the novel therapies utilized to 
treat MM. 
2.  Develop an individualized evidence-based 
patient education plan based on potential 
adverse effects associated with novel therapies 
for MM. 
3.  List evidence-based self-management strategies 
that can ameliorate the adverse effects of novel 
therapies for MM. 
Table 1. Common Adverse Effects of Novel Therapies for MM 
TL LL PL BZ/IZ CZ PS DT 
Cardio-
pulmonary 
effects 
Bradycardi
a 
Shortness 
of breath 
Hypotensio
n 
Shortness 
of breath 
Pneumonia 
Decreased 
Ejection 
fraction 
pneumonia 
Cutaneous 
rash 
u u u 
Fatigue u u u u u u u 
GI adverse 
effects 
Constipatio
n 
Diarrhea 
Constipatio
n  
Diarrhea 
Constipatio
n 
Nausea 
Vomiting 
Diarrhea 
Nausea 
Vomiting 
Diarrhea 
Diarrhea 
Infusion 
reaction 
Dyspnea 
Cough 
Myelosuppres
sion, Anemia, 
neutropenia, 
thrombocytop
enia 
u u u u u u u 
Peripheral 
Neuropathy 
u u u u 
Renal 
Complications 
u 
Sedation u 
DVT or PE u u u 
Abbreviations:  
TL= Thalidomide  LL= Lenalidomide  PL= Pomalidomide  BZ/IZ= Bortezomib/Ixazomib  
CZ= Carfilzomib   PS= Panobinostat  DT= Daratumumab 
Reference: 
Melnyk, B.M., & Fineout-Overholt, E. (2011). Evidence-based 
 practice in nursing and healthcare: A guide to best practice (2nd 
 ed., p. 13). Philadelphia, PA: Lippincott Williams and Wilkins. 
